GBS Inc. (GBS)

$0.72

+0.01 (+0.70%)
Rating:
Recommendation:
-
Symbol GBS
Price $0.72
Beta 0.000
Volume Avg. 0.07M
Market Cap 10.721M
Shares () -
52 Week Range 0.381-4.87
1y Target Est -
DCF Unlevered GBS DCF ->
DCF Levered GBS LDCF ->
ROE -30.56% Strong Sell
ROA -25.24% Sell
Operating Margin -
Debt / Equity 64.47% Buy
P/E -
P/B 1.22 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GBS news


Mr. Harry Simeonidis
Healthcare
Medical Devices
NASDAQ Global Market

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.